Ardelyx stock rockets ntawm hnyav ntim tom qab zoo FDA vaj huam sib luag pov npav rau kev kho mob raum

Shares ntawm Ardelyx Inc.
ARDX,
+ 35.66%
rocketed 75.4% ntawm hnyav ntim mus rau 16-lub hlis siab nyob rau hauv premarket trading hnub Thursday, tom qab ib tug pab tswv yim ntawm lub US Food and Drug Administration tau pov ntawv pom zoo tias cov txiaj ntsig ntawm lub tuam txhab biopharmaceutical kho rau mob raum (CKD) ntawm kev lim ntshav, XPHOZAH, ntau dua qhov txaus ntshai. Kev lag luam ntim yog 11.7 lab shares ua ntej qhib, piv nrog rau tag nrho-hnub nruab nrab ntawm 4.3 lab shares. Qhov ntawd ua rau Ardelyx cov khoom lag luam tau txais txiaj ntsig loj tshaj plaws thiab nquag nquag hauv khw muag khoom ua ntej. Pawg neeg pov npav tuaj tom qab Ardelyx tau thov rov hais dua FDA Ua tiav Tsab Ntawv Teb (CRL) tau txais thaum Lub Xya Hli 2021 hais txog Daim Ntawv Thov Tshuaj Tshiab (NDA) rau nws txoj kev kho CKD. "Peb muaj kev cia siab tom qab kev sib tham niaj hnub no tias cov ntaub ntawv, kev xav ntawm pawg neeg tawm tswv yim, cov kev xav tau ntawm cov neeg mob, thiab lub suab nrov ntawm lub zej zog nephrology yuav raug cuam tshuam los ntawm FDA qhov kev txiav txim siab ntawm peb qhov kev thov rov hais dua," said Ardelyx Chief Executive Mike Raab. . Cov Tshuag tau nce 13.0% nyob rau peb lub hlis dhau los txog rau hnub Wednesday, thaum iShares Biotechnology ETF
IB,
-1.59%
tau nce 2.9% thiab S & P 500
SPX,
-1.21%
tau poob 7.4%.